The broad clinical phenotype of Type 1 diabetes at presentation

Diabetic Medicine

Volumn 30, Issue 2, 2013, Pages 170-178

  Merger, S R ^a   Leslie, R D ^b   Boehm, B O ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE DECARBOXYLASE 65; HLA ANTIGEN; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; INSULIN; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; ORAL ANTIDIABETIC AGENT; PANCREAS ISLET CELL ANTIBODY; PROTEIN; PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG; ZINC TRANSPORTER 8;

ALLELE; CLINICAL FEATURE; DIABETIC DIET; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; INSULITIS; KETOSIS PRONE DIABETES MELLITUS; LATENT AUTOIMMUNE DIABETES MELLITUS OF THE YOUNG; LATENT AUTOIMMUNE DIABETES OF ADULT; PANCREAS TRANSPLANTATION; PHENOTYPE; POLYDIPSIA; POLYURIA; REVIEW; SLOWLY PROGRESSIVE INSULIN DEPENDENT DIABETES MELLITUS; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGE OF ONSET; AUTOANTIBODIES; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUTAMATE DECARBOXYLASE; HLA-DQ ANTIGENS; HUMANS; INFANT; INSULIN-SECRETING CELLS; MALE; PHENOTYPE; RISK ASSESSMENT;

EID: 84872709226     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12048     Document Type: Review

References (86)

1. Beaser SB. The clinical characteristics of early diabetes mellitus. N Engl J Med 1948; 239: 765-769.
2. Duncan GG. Early clinical picture of diabetes. Williams RH, ed. Diabetes. New York: Paul B. Hoeber Inc., 1960; 370-380.
3. Tuomi T. Type 1 and type 2 diabetes: what do they have in common? Diabetes 2005; 54: S40-S45.
4. Leslie RD. Predicting adult-onset autoimmune diabetes: clarity from complexity. Diabetes 2010; 59: 330-331.
5. Heisenberg W. Über den anschaulichen Inhalt der quantentheoretischen Kinematik und Mechanik. Zeitschrift für Physik 1927; 43: 172-198.
6. American Diabetes Association. Clinical practice recommendations 2000. Diabetes Care 2000; 23: S1-S116.
7. Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974; 2: 1279-1283.
8. Palmer JP, Asplin CM, Clemons P, Lyen K, Tatpati O, Raghu PK, et al. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 1983; 222: 1337-1339.
9. Bingley PJ, Bonifacio E, Mueller PW. Diabetes antibody standardization program: first assay proficiency evaluation. Diabetes 2003; 52: 1128-1136.
10. Torn C, Mueller PW, Schlosser M, Bonifacio E, Bingley PJ. Diabetes Antibody Standardization pProgram: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 2008; 51: 846-852.
11. Schlosser M, Mueller PW, Torn C, Bonifacio E, Bingley PJ. Diabetes Antibody Standardization Program: evaluation of assays for insulin autoantibodies. Diabetologia; 53: 2611-2620.
12. Seissler J, de Sonnaville JJ, Morgenthaler NG, Steinbrenner H, Glawe D, Khoo-Morgenthaler UY, et al. Immunological heterogeneity in type I diabetes: presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease. Diabetologia 1998; 41: 891-897.
13. Warncke K, Frohlich-Reiterer EE, Thon A, Hofer SE, Wiemann D, Holl RW. Polyendocrinopathy in children, adolescents, and young adults with type 1 diabetes: a multicenter analysis of 28 671 patients from the German/Austrian DPV-Wiss database. Diabetes Care 2010; 33: 2010-2012.
14. Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007; 104: 17040-17045.
15. Verge CF, Howard NJ, Rowley MJ, Mackay IR, Zimmet PZ, Egan M, et al. Anti-glutamate decarboxylase and other antibodies at the onset of childhood IDDM: a population-based study. Diabetologia 1994; 37: 1113-1120.
16. Kobayashi T. Subtype of insulin-dependent diabetes mellitus (IDDM) in Japan: slowly progressive IDDM-the clinical characteristics and pathogenesis of the syndrome. Diabetes Res Clin Pract 1994; 24: S95-S99.
17. Naik RG, Brooks-Worrell BM, Palmer JP. Latent autoimmune diabetes in adults. J Clin Endocrinol Metab 2009; 94: 4635-4644.
18. Kobayashi T, Nishida Y, Tanaka S, Aida K. Pathological changes in the pancreas of fulminant type 1 diabetes and slowly progressive insulin-dependent diabetes mellitus (SPIDDM): innate immunity in fulminant type 1 diabetes and SPIDDM. Diabetes Metab Res Rev 2011; 27: 965-970.
19. Husebye ES, Anderson MS. Autoimmune polyendocrine syndromes: clues to type 1 diabetes pathogenesis. Immunity 2010; 32: 479-487.
20. Baker JR Jr. Autoimmune endocrine disease. J Am Med Assoc 1997; 278: 1931-1937.
21. Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. N Engl J Med 2000; 342: 301-307.
22. Wolfsdorf J, Craig ME, Daneman D, Dunger D, Edge J, Lee W, et al. Diabetic ketoacidosis in children and adolescents with diabetes. Pediatr Diabetes 2009; 10: S118-S133.
23. Beyan H, Riese H, Hawa MI, Beretta G, Davidson HW, Hutton JC, et al. Glycotoxin and autoantibodies are additive environmentally determined predictors of type 1 diabetes: a twin and population study. Diabetes 2012; 61: 1192-1198.
24. Leslie RD. Delli Castelli M. Age-dependent influences on the origins of autoimmune diabetes: evidence and implications. Diabetes 2004; 53: 3033-3040.
25. Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP et al. Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2006; 29: 643-649.
26. Balasubramanyam A, Garza G, Rodriguez L, Hampe CS, Gaur L, Lernmark A, et al. Accuracy and predictive value of classification schemes for ketosis-prone diabetes. Diabetes Care 2006; 29: 2575-2579.
27. Graham J, Hagopian WA, Kockum I, Li LS, Sanjeevi CB, Lowe RM, et al. Genetic effects on age-dependent onset and islet cell autoantibody markers in type 1 diabetes. Diabetes 2002; 51: 1346-1355.
28. Sabbah E, Savola K, Ebeling T, Kulmala P, Vahasalo P, Ilonen J, et al. Genetic, autoimmune, and clinical characteristics of childhood- and adult-onset type 1 diabetes. Diabetes Care 2000; 23: 1326-1332.
29. Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care 2000; 23: 1516-1526.
30. Kobayashi T, Tamemoto K, Nakanishi K, Kato N, Okubo M, Kajio H, et al. Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care 1993; 16: 780-788.
31. Pozzilli P, Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention. Diabetes Care 2001; 24: 1460-1467.
32. Palmer JP, Hirsch IB. What's in a name: latent autoimmune diabetes of adults, type 1.5, adult-onset, and type 1 diabetes. Diabetes Care 2003; 26: 536-538.
33. Hawa MI, Fava D, Medici F, Deng YJ, Notkins AL, De Mattia G, et al. Antibodies to IA-2 and GAD65 in type 1 and type 2 diabetes: isotype restriction and polyclonality. Diabetes Care 2000; 23: 228-233.
34. Brophy S, Yderstraede K, Mauricio D, Hunter S, Hawa M, Pozzilli P, et al. Time to insulin initiation cannot be used in defining latent autoimmune diabetes in adults. Diabetes Care 2008; 31: 439-441.
35. Kyvik KO, Nystrom L, Gorus F, Songini M, Oestman J, Castell C, et al. The epidemiology of Type 1 diabetes mellitus is not the same in young adults as in children. Diabetologia 2004; 47: 377-384.
36. Pham MN, Hawa MI, Pfleger C, Roden M, Schernthaner G, Pozzilli P, et al. Pro- and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: Action LADA 4. Diabetologia 2011; 54: 1630-1638.
37. Baroni MG, D'Andrea MP, Montali A, Pannitteri G, Barilla F, Campagna F, et al. A common mutation of the insulin receptor substrate-1 gene is a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 1999; 19: 2975-2980.
38. Andersen MK, Lundgren V, Turunen JA, Forsblom C, Isomaa B, Groop PH, et al. Latent autoimmune diabetes in adults differs genetically from classical type 1 diabetes diagnosed after the age of 35 years. Diabetes Care 2010; 33: 2062-2064.
39. Cervin C, Lyssenko V, Bakhtadze E, Lindholm E, Nilsson P, Tuomi T, et al. Genetic similarities between latent autoimmune diabetes in adults, type 1 diabetes, and type 2 diabetes. Diabetes 2008; 57: 1433-1437.
40. Kobayashi T, Tanaka S, Harii N, Aida K, Shimura H, Ohmori M, et al. Immunopathological and genetic features in slowly progressive insulin-dependent diabetes mellitus and latent autoimmune diabetes in adults. Ann N Y Acad Sci 2006; 1079: 60-66.
41. Sabbah E, Savola K, Kulmala P, Veijola R, Vahasalo P, Karjalainen J, et al. Diabetes-associated autoantibodies in relation to clinical characteristics and natural course in children with newly diagnosed type 1 diabetes. The Childhood Diabetes in Finland Study Group. J Clin Endocrinol Metab 1999; 84: 1534-1539.
42. Lohmann T, Nietzschmann U, Kiess W. 'Lady-like': is there a latent autoimmune diabetes in the young? Diabetes Care 2000; 23: 1707-1708.
43. Umpierrez GE, Smiley D, Kitabchi AE. Narrative review: ketosis-prone type 2 diabetes mellitus. Ann Intern Med 2006; 144: 350-357.
44. Umpierrez GE. Ketosis-prone type 2 diabetes: time to revise the classification of diabetes. Diabetes Care 2006; 29: 2755-2757.
45. Teupe B, Bergis K. Prospective randomized 2-year clinical study comparing additional metformin treatment with reducing diet in type 2 diabetes. Diabete Metab 1991; 17: 213-217.
46. Roglic G, Colhoun HM, Stevens LK, Lemkes HH, Manes C, Fuller JH. Parental history of hypertension and parental history of diabetes and microvascular complications in insulin-dependent diabetes mellitus: the EURODIAB IDDM Complications Study. Diabet Med 1998; 15: 418-426.
47. Erbey JR, Kuller LH, Becker DJ, Orchard TJ. The association between a family history of type 2 diabetes and coronary artery disease in a type 1 diabetes population. Diabetes Care 1998; 21: 610-614.
48. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the Diabetes Control and Complications Trial. J Am Med Assoc 1998; 280: 140-146.
49. Harjutsalo V, Sjoberg L, Tuomilehto J. Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study. Lancet 2008; 371: 1777-1782.
50. Moltchanova EV, Schreier N, Lammi N, Karvonen M. Seasonal variation of diagnosis of Type 1 diabetes mellitus in children worldwide. Diabet Med 2009; 26: 673-678.
51. Finel E, Giroux JD, Metz C, Robert JJ, Robert O, Sadoun E et al. Diabete neonatal vrai associe a une maladie auto-immune (Neonatal diabetes mellitus associated with an autoimmune disease). Arch Pediatr 1996; 3: 782-784.
52. Metz C, Cave H, Bertrand AM, Deffert C, Gueguen-Giroux B, Czernichow P, et al. Neonatal diabetes mellitus: chromosomal analysis in transient and permanent cases. J Pediatr 2002; 141: 483-489.
53. Achenbach P, Bonifacio E, Koczwara K, Ziegler AG. Natural history of type 1 diabetes. Diabetes 2005; 54: S25-S31.
54. Hermann R, Lipponen K, Kiviniemi M, Kakko T, Veijola R, Simell O, et al. Lymphoid tyrosine phosphatase (LYP/PTPN22) Arg620Trp variant regulates insulin autoimmunity and progression to type 1 diabetes. Diabetologia 2006; 49: 1198-1208.
55. Howson JM, Rosinger S, Smyth DJ, Boehm BO, Todd JA. Genetic analysis of adult-onset autoimmune diabetes. Diabetes 2011; 60: 2645-2653.
56. Gillespie KM, Bain SC, Barnett AH, Bingley PJ, Christie MR, Gill GV, et al. The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. Lancet 2004; 364: 1699-1700.
57. Steck AK, Johnson K, Barriga KJ, Miao D, Yu L, Hutton JC, et al. Age of islet autoantibody appearance and mean levels of insulin, but not GAD or IA-2 autoantibodies, predict age of diagnosis of type 1 diabetes: diabetes autoimmunity study in the young. Diabetes Care 2011; 34: 1397-1399.
58. Vandewalle CL, Decraene T, Schuit FC, De Leeuw IH, Pipeleers DG, Gorus FK. Insulin autoantibodies and high titre islet cell antibodies are preferentially associated with the HLA DQA1 0301-DQB1 0302 haplotype at clinical type 1 (insulin-dependent) diabetes mellitus before age 10 years, but not at onset between age 10 and 40 years. The Belgian Diabetes Registry. Diabetologia 1993; 36: 1155-1162.
59. Ziegler AG, Bonifacio E. Age-related islet autoantibody incidence in offspring of patients with type 1 diabetes. Diabetologia 2012; 55: 1937-1943.
60. In't Veld P. Insulitis in human type 1 diabetes: the quest for an elusive lesion. Islets; 3: 131-138.
61. Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol 2009; 155: 173-181.
62. Klinke DJ 2nd. Extent of beta cell destruction is important but insufficient to predict the onset of type 1 diabetes mellitus. PLoS One 2008; 3: e1374.
63. Kawasaki E, Yamaguchi Y, Nagataki S. Insulitis in an autoimmune-mediated patient originally classified as having type 2 diabetes. Diabetes Care 1999; 22: 541-542.
64. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Trial. A randomized, controlled trial. Ann Intern Med 1998; 128: 517-523.
65. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care 2003; 26: 832-836.
66. Hills CE, Brunskill NJ. Cellular and physiological effects of C-peptide. Clin Sci (Lond) 2009; 116: 565-574.
67. Michels AW, Eisenbarth GS. Immune intervention in type 1 diabetes. Semin Immunol 2011; 23: 214-219.
68. Cravedi P, Remuzzi A, Remuzzi G. Comment on: Robertson (2010) Islet transplantation a decade later and strategies for filling a half-full glass. Diabetes 2010; 59: 1285-1291. Diabetes; 59: e13; author reply e14.
69. Cravedi P, van der Meer IM, Cattaneo S, Ruggenenti P, Remuzzi G. Successes and disappointments with clinical islet transplantation. Adv Exp Med Biol 2010; 654: 749-769.
70. Intensive diabetes management: implications of the DCCT and UKPDS. Diabetes Educ 2002; 28: 735-740.
71. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. J Am Med Assoc 2003; 290: 2159-2167.
72. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. J Am Med Assoc 2002; 287: 2563-2569.
73. Type 1 diabetes: benefits of intensive insulin therapy. Patients should control blood glucose strictly. Prescrire Int 2002; 11: 61.
74. Brophy S, Davies H, Mannan S, Brunt H, Williams R. Interventions for latent autoimmune diabetes (LADA) in adults. Cochrane Database Syst Rev 2011; 9: CD006165.
75. Nishimura R, LaPorte RE, Dorman JS, Tajima N, Becker D, Orchard TJ. Mortality trends in type 1 diabetes. The Allegheny County (Pennsylvania) Registry 1965-1999. Diabetes Care 2001; 24: 823-827.
76. Secrest AM, Becker DJ, Kelsey SF, LaPorte RE, Orchard TJ. All-cause mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes: the Allegheny County type 1 diabetes registry. Diabetes Care 2010; 33: 2573-2579.
77. Secrest AM, Becker DJ, Kelsey SF, Laporte RE, Orchard TJ. Cause-specific mortality trends in a large population-based cohort with long-standing childhood-onset type 1 diabetes. Diabetes 2010; 59: 3216-3222.
78. Skrivarhaug T, Bangstad HJ, Stene LC, Sandvik L, Hanssen KF, Joner G. Long-term mortality in a nationwide cohort of childhood-onset type 1 diabetic patients in Norway. Diabetologia 2006; 49: 298-305.
79. Soedamah-Muthu SS, Chaturvedi N, Witte DR, Stevens LK, Porta M, Fuller JH. Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). Diabetes Care 2008; 31: 1360-1366.
80. Heptulla RA, Stewart A, Enocksson S, Rife F, Ma TY, Sherwin RS, et al. In situ evidence that peripheral insulin resistance in adolescents with poorly controlled type 1 diabetes is associated with impaired suppression of lipolysis: a microdialysis study. Pediatr Res 2003; 53: 830-835.
81. Perseghin G, Lattuada G, Danna M, Sereni LP, Maffi P, De Cobelli F, et al. Insulin resistance, intramyocellular lipid content, and plasma adiponectin in patients with type 1 diabetes. Am J Physiol Endocrinol Metab 2003; 285: E1174-E1181.
82. Forssas EH, Keskimaki IT, Reunanen AR, Koskinen SV. Coronary heart disease among diabetic and nondiabetic people - socioeconomic differences in incidence, prognosis and mortality. J Diabetes Complications 2008; 22: 10-17.
83. Olson JC, Erbey JR, Williams KV, Becker DJ, Edmundowicz D, Kelsey SF, et al. Subclinical atherosclerosis and estimated glucose disposal rate as predictors of mortality in type 1 diabetes. Ann Epidemiol 2002; 12: 331-337.
84. Banerji MA, Dham S. A comparison of classification schemes for ketosis-prone diabetes. Nat Clin Pract Endocrinol Metab 2007; 3: 506-507.
85. Haaland WC, Scaduto DI, Maldonado MR, Mansouri DL, Nalini R, Iyer D, et al. Ab-subtype of ketosis-prone diabetes is not predominantly a monogenic diabetic syndrome. Diabetes Care 2009; 32: 873-877.
86. Nalini R, Ozer K, Maldonado M, Patel SG, Hampe CS, Guthikonda A et al. Presence or absence of a known diabetic ketoacidosis precipitant defines distinct syndromes of 'A-b+' ketosis-prone diabetes based on long-term b-cell function, human leukocyte antigen class II alleles and sex predilection. Metabolism 2010; 59: 1448-1455.